KUALA LUMPUR: An increase in the cost of raw materials for the production of pharmaceuticals due to strains on the supply chain could have an impact on domestic pharmaceutical players, said RHB Research.
However, the research firm expects the earnings impact to be minimal as cost spikes may not happen as soon (earliest by 2Q23), given that the major India API supplier still has four to six months of inventory.
Already a subscriber? Log in
The Star Festive Promo: Get 35% OFF Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
